Fresenius SE & Co KGaA - German healthcare firm - Says Fresenius Kabi is further expanding its Austrian facilities, and will invest more than EUR60 million through 2023 to expand capacity and upgrade infrastructure at its production plant in Graz and packaging center in nearby Werndorf.
Fresenius Kabi, a subsidiary of Fresenius SE & Co, produces liquid pharmaceuticals and clinical nutrition products for the Austrian and international markets in Graz.
Current stock price: EUR34.96
Year-to-date change: down 7.6%
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.